Miguel Inca-Martinez

Miguel Inca-Martinez

Auto-generated profile, based on publicly available information

Miguel Inca-Martinez

Genomic Sciences and Systems Biology, Cleveland Clinic Research, Cleveland Clinic Foundation, Cleveland, OH, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2015 in Molecular Neurodegeneration
Verified
Journal Article
Open access
PDF file
IMIgnacio F. Mata
Ignacio F. Mata
Yongwoo JangYongwoo Jang
Yongwoo Jang
CKChun-Hyung Kim
Chun-Hyung Kim
DHDavid S. Hanna
David S. Hanna
MDMichael O. Dorschner
Michael O. Dorschner
CZCyrus P. Zabetian
Cyrus P. Zabetian
To identify the causal gene in a multi-incident U.S. kindred with Parkinson’s disease (PD). We characterized a family with a classical PD phenotype in which 7 individuals (5 males and 2 females) were affected with a mean age at onset of 46.1 years (range, 29-57 years). We performed whole exome sequencing on 4 affected and 1 unaffected family members. Sanger-sequencing was then used to verify and genotype all candidate variants in the remainder of the pedigree. Cultured cells transfected with wild-type or mutant constructs were used to characterize proteins of interest. We identified a missense mutation (c.574G > A; p.G192R) in the RAB39B gene that closely segregated with disease and exhibited X-linked dominant inheritance with reduced penetrance in females. The mutation occurred in a highly conserved amino acid residue and was not observed among 87,725 X chromosomes in the Exome Aggregation Consortium dataset. Sequencing of the RAB39B coding region in 587 familial PD cases yielded two additional mutations (c.428C > G [p.A143G] and c.624_626delGAG [p.R209del]) that were predicted to be deleterious in silico but occurred in families that were not sufficiently informative to assess segregation with disease. Experiments in PC12 and SK-N-BE(2)C cells demonstrated that p.G192R resulted in mislocalization of the mutant protein, possibly by altering the structure of the hypervariable C-terminal domain which mediates intracellular targeting. Our findings implicate RAB39B, an essential regulator of vesicular-trafficking, in clinically typical PD. Further characterization of normal and aberrant RAB39B function might elucidate important mechanisms underlying neurodegeneration in PD and related disorders.

1 June 2019 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
CVCARLOS VELEZ
CARLOS VELEZ
OLOswaldo Lorenzo-Betancor
Oswaldo Lorenzo-Betancor
MJMarlene Jimenez-Del-Rio
Marlene Jimenez-Del-Rio
SMSonia Moreno
Sonia Moreno
FLFrancisco Lopera
Francisco Lopera
IMIgnacio F. Mata
Ignacio F. Mata

2 June 2017 in npj Parkinson's Disease
Verified
Journal Article
Open access
PDF file
Mario Cornejo-OlivasMario Cornejo-Olivas
Mario Cornejo-Olivas
LTLuis Torres
Luis Torres
MVMario R. Velit-Salazar
Mario R. Velit-Salazar
MIMiguel Inca-Martinez
Miguel Inca-Martinez
PMPilar Mazzetti
Pilar Mazzetti
IMIgnacio F. Mata
Ignacio F. Mata
Mutations in Leucine Repeat Rich Kinase 2 (LRRK2), primarily located in codons G2019 and R1441, represent the most common genetic cause of Parkinson’s disease in European-derived populations. However, little is known about the frequency of these mutations in Latin American populations. In addition, a prior study suggested that a LRRK2 polymorphism (p.Q1111H) specific to Latino and Amerindian populations might be a risk factor for Parkinson’s disease, but this finding requires replication. We screened 1734 Parkinson’s disease patients and 1097 controls enrolled in the Latin American Research Consortium on the Genetics of Parkinson’s disease (LARGE-PD), which includes sites in Argentina, Brazil, Colombia, Ecuador, Peru, and Uruguay. Genotypes were determined by TaqMan assay (p.G2019S and p.Q1111H) or by sequencing of exon 31 (p.R1441C/G/H/S). Admixture proportion was determined using a panel of 29 ancestry informative markers. We identified a total of 29 Parkinson’s disease patients (1.7%) who carried p.G2019S and the frequency ranged from 0.2% in Peru to 4.2% in Uruguay. Only two Parkinson’s disease patients carried p.R1441G and one patient carried p.R1441C. There was no significant difference in the frequency of p.Q1111H in patients (3.8%) compared to controls (3.1%; OR 1.02, p = 0.873). The frequency of LRRK2-p.G2019S varied greatly between different Latin American countries and was directly correlated with the amount of European ancestry observed. p.R1441G is rare in Latin America despite the large genetic contribution made by settlers from Spain, where the mutation is relatively common.

1 May 2015 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
Mario Cornejo-OlivasMario Cornejo-Olivas
Mario Cornejo-Olivas
LTLuis Torres
Luis Torres
IMIgnacio F. Mata
Ignacio F. Mata
PMPilar Mazzetti
Pilar Mazzetti
DRDiana Rivas
Diana Rivas
JLJames B. Leverenz
James B. Leverenz

21 December 2016 in European Journal of Human Genetics
Verified
Journal Article
Closed access
CKChris Kay
Chris Kay
ITIndira Tirado-Hurtado
Indira Tirado-Hurtado
Mario Cornejo-OlivasMario Cornejo-Olivas
Mario Cornejo-Olivas
JCJennifer A Collins
Jennifer A Collins
GWGalen Wright
Galen Wright
MHMichael R. Hayden
Michael R. Hayden

3 January 2020 in The Cerebellum
Verified
Journal Article
Closed access
PDF file
ONOn Behalf Of Rede Neurogenetica
On Behalf Of Rede Neurogenetica
Mario Cornejo-OlivasMario Cornejo-Olivas
Mario Cornejo-Olivas
MIMiguel Inca-Martinez
Miguel Inca-Martinez
RCRaphael Machado Castilhos
Raphael Machado Castilhos
GFGabriel Vasata Furtado
Gabriel Vasata Furtado
LJLaura Bannach Jardim
Laura Bannach Jardim